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Abstract
Background: Studies have shown that plasma high density lipoprotein cholesterol levels are negatively correlated
with the development of atherosclerosis, whereas epidemiological studies have also shown that plasma
sphingomyelin level is an independent risk factor for atherosclerosis.
Methods: To evaluate the relationship between cellular sphingomyelin level and cholesterol metabolism, we
created two cell lines that overexpressed sphingomyelin synthase 1 or 2 (SMS1 or SMS2), using the Tet-off
expression system.
Results: We found that SMS1 or SMS2 overexpression in Huh7 cells, a human hepatoma cell line, significantly
increased the levels of intracellular sphingomyelin, cholesterol, and apolipoprotein A-I and decreased levels of
apolipoprotein A-I and cholesterol in the cell culture medium, implying a defect in both processes.
Conclusions: Our findings indicate that the manipulation of sphingomyelin synthase activity could influence the
metabolism of sphingomyelin, cholesterol and apolipoprotein A-I.
Background
Atherosclerosis (AS) is the main cause of cardiovascular
disease and stroke and a prevalent chronic disease. The
metabolism of cholesterol in vivo is tightly associated
with AS [1]. Studies have shown that levels of high den-
sity lipoprotein cholesterol (HDL-C) in the plasma were
negatively correlated with atherosclerosis, whereas
increasing plasma HDL-C levels could reduce the devel-
opment of AS [2]. The mechanism of this effect may be
due to high density lipoprotein (HDL) mediated reverse
cholesterol transport (RCT), a process used to remove
excess cholesterol from peripheral tissues to the liver for
excretion. Many lipids and protein molecules are
involved in RCT [3], of which Apolipoprotein A-I (Apo
A-I) and membrane sphingomyelin are two.
Apo A-I is synthesized in the liver and intestine and is
a major protein component of HDL. Apo A-I can serves
as an acceptor for phospholipids and cholesterol
effluxed from peripheral tissues through the ATP bind-
ing cassette transporter A1 (ABCA1) to form nascent
HDL particles [4,5]. The nascent particles continue to
accept the cholesterol effluxed through ATP binding
cassette transporter G1 (ABCG1) to form mature HDL
[3,6]. Scavenger receptor BI (SR-BI), an HDL receptor
on liver cell membranes, can mediate selective uptake of
HDL lipid, and cholesterol can be taken up into the
liver and excreted into bile [3,7].
Significant evidence has been presented to confirm the
existence of lipid rafts in membranes enriched with
sphingolipids and cholesterol in the liquid-ordered
phase. Sphingomyelin (SM) is a major component of
sphingolipids [8]. Studies have shown that ABCA1,
ABCG1 and SR-BI are associated with lipid rafts [9-11].
Therefore, changes in SM biosynthesis could have an
impact on lipoprotein metabolism and membrane pro-
teins (ABCA1, ABCG1 and SR-BI), thus influencing
lipoprotein and cholesterol levels in the circulation.
Epidemiological investigations have shown that an
increased plasma SM levels is an independent risk factor
for AS. Recent studies have found that SM accumulates
in atherosclerotic plaques [12,13]. Because SM might
affect the activity of lecithin cholesterol acyltransferase
(LCAT) and lipoprotein lipase (LPL), the inhibition of
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SM biosynthesis might reduce lipoprotein SM content
and improve cholesterol distribution in lipoproteins by
enhancing RCT [14].
Serine palmitoyltransferase (SPT) and sphingomyelin
synthase (SMS) are two critical enzymes that play
important roles in the multienzymatic steps of SM bio-
synthesis. Pharmacologic inhibition of SPT caused a sig-
nificant decrease of plasma SM levels and AS plague
size in mice [15,16]. SMS is the last critical enzyme for
SM biosynthesis and has two isoforms (SMS1 and
SMS2). SMS1 is located on the cis-, medial-Golgi appa-
ratus, and SMS2 is found in plasma membranes [17,18].
Our laboratory has found that SMS overexpression
increased SM levels in cells and animals [19,20].
In this study, we investigated the effect of SMS over-
expression on cholesterol accumulation and secretion in
Huh7 cells.
Materials and methods
Preparation of cell lines stably overexpressing SMS1 or
SMS2
A Tet-off system was used to establish the Huh7 cell
lines overexpressing SMS1 or SMS2. Briefly, Huh7 cells
were transfected with the regulator plasmid of pTet-Off
Vector (Clontech) (to express the tTA protein), using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. G418 (250 μg/ml) was used to
select positive clones (named as Huh7-tTA), which were
further transfected with Tet-Off-SMS1-FLAG or Tet-
Off-SMS2-FLAG (SMS1 and SMS2 expression vectors
were purchased from Open Biosystems, USA). The cells
were screened under the pressure of Hygromycin B (250
μg/ml, Amresco) and G418 (250 μg/ml). The monoclo-
nal cell lines that survived under the pressure selection
were chosen and named SMS1 or SMS2 cells.
RT-PCR analysis
Total RNA was isolated from cells with Trizol (Takara).
Two μg of total RNA was reverse-transcribed and the
cDNA was amplified by PCR using a kit (Fermentas).
The PCR products were visualized by electrophoresis on
1.5% agarose gels. b-Actin RNA was used as an internal
control. The primers (Invitrogen) used for the analyses
were the following:
SMS1 sense (5’ - GGCTTCTCAGCGTAGTTGGA -3’);
SMS2 sense (5’-TATTCGCCTCGTCACTTCTGG-3’);




b-actin antisense (5’- GCATTTGCGGTGGACGATG-
GAGG-3’);
Apo A-I sense (5’-CTCTTCCTGACGGGGAGC-3’);












HMG-CoA reductase sense (5’- GGAGTGGCAG-
GACCCCTTTGC -3’);
HMG-CoA reductase antisense (5’- CCAGCCATGG-
CAGAGCCCAC -3’).
The product lengths of SMS1, SMS2, b-actin, Apo A-
I, ABCA1, ABCG1, SR-BI and HMG-CoA reductase are
367 bp, 431 bp, 650 bp, 310 bp, 586 bp, 207 bp, 421 bp
and 617 bp, respectively.
Western blot analysis
Equal amounts of cell homogenates (20 μg protein/lane)
were separated on 10% polyacrylamide gels under dena-
turing conditions. Proteins were electroblotted to a
nitrocellulose membrane that had been incubated with
respective antibodies: FLAG (CST), Apo A-I (Epitomics),
ABCA1 (Boster), ABCG1 (Boster), or SR-BI (Epitomics).
The loading control was glyceraldehyde-3-phosphate
dehydrogenase. The Super Signal West detection kit
(Pierce) was used for the detection step. The maximum
intensity of each band was measured using Image-Pro
Plus version 6.0 software (Media Cybernetics, Inc.).
Sphingomyelin synthase activity assay
Cells were homogenized in a buffer containing 50 mM
Tris-HCl, 1 mM EDTA, 5% sucrose, and protease inhi-
bitors. The homogenate was centrifuged at 5000 rpm
for 10 min, and the supernatant was used to analyze
SMS activity. The reaction system contained 50 mM
Tris-HCl (pH 7.4), 25 mM KCl, C6-NBD-ceramide (0.1
mg/mL) (Invitrogen-MP), and PC (0.01 mg/mL). The
mixture was incubated at 37°C for 2 hours. Lipids were
extracted in chloroform:methanol (2:1), dried under
nitrogen gas, and separated using thin layer chromato-
graphy (TLC) [21]. The plate was scanned with a Phos-
phorImager (Molecular Dynamics; Sunnyvale, CA) and
the intensity of each band was measured using Image-
Pro Plus version 6.0 software (Media Cybernetics, Inc.).
Lysenin treatment and cell mortality measurement
Cells were washed twice in PBS and incubated with lyse-
nin (200 ng/ml) for 1 hr. Cell viability was measured
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using the WST-1 cell proliferation reagent according to
the manufacturer’s instructions (Roche) [22]
Analysis of Apo A- I in the medium by ELISA
ELISA analysis of the Apo A-I in the cell culture med-
ium was done as previously reported [23].
Sphingomyelin and cholesterol measurement
The cell monolayer was washed twice with PBS, and cel-
lular lipids were extracted using n-hexane-2/propanol
(3:2). Aliquots of the extracted lipids were subjected to
analysis. The SM content was measured by a method
previously described [15], and cholesterol was measured
using a commercial available kit (Rongshen).
Statistical Analysis
Data are reported as the mean ± standard deviation
(SD). Statistical analysis was performed using Student’s t
test and one-way ANOVA followed by Tukey’s test. Dif-
ferences were considered significant at P < 0.05.
Results
To investigate the ex vivo role of SMS1 and SMS2, we
utilized the Tet-off system to express SMS1-FLAG and
SMS2-FLAG in Huh 7 cells. RT-PCR of RNA prepared
from the cells indicated that both SMS1-FLAG and
SMS2-FLAG were expressed (Figure 1A), and this
expression was confirmed by Western blot analysis
(Figure 1B). Furthermore, SMS overexpression caused a
significant increase in total SMS activity compared to
controls (Figure 2; P < 0.001).
As shown in Figure 3, SMS overexpression signifi-
cantly increased intracellular levels of SM (P < 0.001).
Because cellular SM levels represent SM levels in all cel-
lular membranes, including the plasma membrane,
endoplasmic reticulum, and Golgi complex, we still do
not know whether SMS1 or SMS2 overexpression has
an effect on SM levels specifically in the plasma mem-
brane. Lysenin is a recently discovered SM-specific cyto-
toxin that recognizes SM only when it forms aggregates
or microdomains [24]. To investigate the effect of SMS1
or SMS2 overexpression on the formation of these
microdomains, we tested both SMS overexpression cell
lines for their sensitivity to lysenin-mediated cytolysis.
As indicated in Figure 4, both cells showed significantly
more sensitive to lysenin-mediated cytolysis than control
cells (P < 0.001).
There is evidence to suggest that sphingomyelin and
cholesterol are linked inside the cells [25]. We therefore
reasoned that the accumulation of SM in the cells might
increase cellular cholesterol levels. To test this hypoth-
esis, we measured cellular cholesterol levels and found
that they were significantly increased in both SMS1 and
SMS2 cells compared to control cells (Figure 3; P <
0.05).
We next sought to determine whether overexpression
of SMS would decrease cholesterol secretion. The
results showed that the contents of cholesterol in the
cell culture medium were significantly decreased in both
SMS1 and SMS2 overexpressing cells (Figure 5; P <
0.05). We then measured ABCA1, ABCG1, SR-BI
mRNA and protein levels, as well as HMG-CoA reduc-
tase mRNA levels. As shown in Figure 6, SMS1 and
SMS2 overexpression can upregulate ABCA1, ABCG1,
and SR-BI mRNA and protein levels and downregulate
HMG-CoA reductase mRNA levels, as compared with
controls (Figure 6, 7; P < 0.05 and 0.001, respectively).
To investigate the relationship between SMS overex-
pression and lipoprotein metabolism, we measured Apo
A-I levels inside the cells and in the cell culture med-
ium. As shown in Figure 8, SMS overexpression signifi-
cantly increased cellular Apo A-I content (Figure 8B;
P < 0.001), which might be due to decreasing Apo A-I
secretion (Figure 8C; P < 0.001). Apo A-I mRNA
expression between SMS cells and control cells were not
significantly different (Figure 8A; P > 0.05).
Discussion
Previously, we had confirmed that overexression SMS1
or SMS2 can accelerate development of atherosclerosis
in mice. But the studies were in mice[20], to further
investigate the effect of SM on the atherosclerosis in
human cells, in the present study, we demonstrated that
Huh7 cells with higher SMS activity 1) had increased
cellular SM and cholesterol content and decreased cho-
lesterol secretion; 2) had increased cellular Apo A-I con-
tent and decreased Apo A-I secretion, but normal Apo
A-I mRNA expression; and 3) had increased expression
Figure 1 Detection of SMS-FLAG in control (Huh7-tTA), SMS1 and SMS2 overexpressing cells by RT-PCR (A) and Western blot (B).
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of ABCA1, ABCG1 and SR-BI mRNA and protein levels
as well as decreased expression of HMG-CoA reductase
mRNA. Thus, SMS activity is closely related to choles-
terol metabolism.
In this study, we demonstrated an interesting phenom-
enon: SMS overexpression-mediated SM content changes
paralleled the cholesterol content changes in the cells. The
interaction of SM, cholesterol, and glycosphingolipid
drives the formation of plasma membrane rafts [8]. Rafts
are formed in the Golgi apparatus and are targeted to
plasma membranes, where they are thought to exist as
floating islands within the sea of bulk membrane [26]. Up
to 70% of membrane SM is found in rafts [27]. The rela-
tive proportions of both SM and cholesterol appear critical
for raft stability because depletion of cholesterol or
supplementation of the SM pool abolishes or (re)estab-
lishes, respectively, the detergent insolubility of the
domains and their sorting capacity [28-30]. As demon-
strated in artificial membrane systems, cholesterol facili-
tates the formation of sphingolipid-containing
microdomains [31]. Ito et al. [25] reported that the diges-
tion of membrane by extracellular sphingomyelinase
(SMase, a SM hydrolase) increased the incorporation of
cellular cholesterol into generated HDL and that this
increase was diminished by supplement of endogenous or
exogenous SM to the cells. Patients with Niemann-Pick
disease (NPD-B) can not hydrolyze SM because of defec-
tive SMase, which results in the deposition of a large num-
ber of SM and cholesterol in the liver and nervous system
[32]. Our results imply that SM and cholesterol in the
rafts might closely interact with or anchor one other.
Our results also showed that SMS overexpression-
mediated cholesterol accumulation (Figure 3) was not
related to increased production, because HMG-
CoA reductase mRNA expression was downregulated
Figure 2 SMS activity assay. Values shown are means ± SD (n =
6), **P < 0.001 compared to control (Huh7-tTA).
Figure 3 Determination of the cellular SM and cholesterol
content. Values shown are means ± SD (n = 3), *P < 0.05; **P <
0.001 compared to control (Huh7-tTA).
Figure 4 Lysenin-mediated cytotoxicity. Values shown are means
± SD (n = 4), *P < 0.001 compared to control (Huh7-tTA).
Figure 5 Determination of the cholesterol concentrations in
the medium. Values shown are means ± SD (n = 3), *P < 0.05
compared to control (Huh7-tTA).
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Figure 6 The expression of ABCA1, ABCG1 and SR-BI. A. RT-PCR analysis; B. Western blot analysis. Values shown are means ± SD (n = 3), *P
< 0.05; **P < 0.001 compared to control (Huh7-tTA).
Figure 7 mRNA analysis of HMG-CoA reductase by RT-PCR. Values shown are means ± SD (n = 3), **P < 0.001 compared to control (Huh7-
tTA).
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(Figure 7). A reasonable explanation for this result fol-
lows: 1) elevated SM can increase cholesterol seques-
tration; 2) Apo A-I is the acceptor of cellular
cholesterol efflux, so decreasing the secretion of Apo
A-I might result in reduction of cholesterol efflux; and
3) as an HDL receptor, SR-BI in hepatic cells involves
selective HDL cholesterol ester uptake and cholesterol
efflux[3,7] and increasing SR-BI expression (Figure 6)
might promote cholesterol uptake and cholesterol
efflux, but the mass of upake were more than the
efflux, Probably, cholesterol in Golgi complex or endo-
plasmic reticulum (ER) was increased along with SM.
Our previous study also showed that SMS overexpres-
sion led to upregulation of SR-BI in vivo [20]. Apo A-I
plays an important role in anti-atherosclerosis. There
is a negative relationship between plasma HDL-C
Figure 8 Analysis of Apo A-I in the cells and medium. A. Apo A-I analysis in the cells by RT-PCR; B. Apo A-I analysis in the cell by Western
blot; C. Apo A-I analysis in the medium by ELISA. Values shown are means ± SD (n = 3). **P < 0.001 compared to control (Huh7-tTA).
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levels and atherosclerosis, and Apo A-I is a major pro-
tein component of HDL [2,4]. Because Apo A-I mRNA
expression had no change, increased cellular Apo A-I
content in SMS-overexpressing Huh7 cells might be
due to decreased Apo A-I secretion (Figure 8).
Downregulation of HMG-CoA reductase expression in
SMS overexpressed cells reflects a feedback inhibition
mechanism by elevating cellular cholesterol content
(Figures 3 and 7). Upregulation of ABCA1 and ABCG1
expression in SMS overexpressing cells might be a self-
protective positive feedback mechanism (Figure 6), con-
sistent with a reported study that showed that in epoxy-
cholesterol treated macrophages, where an increase in
cholesterol synthesis led to the upregulation of ABCA1
and ABCG1 [33].
The deposition of cholesterol in plaques is one of the
characteristics of atherosclerosis. Our previous studies
showed that SMS overexpression resulted in changes
in plasma lipid and lipoprotein metabolism and
increased the atherogenic potential in mice [20]. All
evidence indicates that the inhibition of SM biosynth-
esis might be a new pathway for the treatment of AS
and that SMS might become a potential target for AS
treatment.
Conclusions
Cellular SM levels are positively related to cellular cho-
lesterol levels and SMS overexpression-mediated cellular
SM content changes are related to cellular Apo A-I con-
tent and secretion. SMS might be a potential target for
the treatment of AS.
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